InterCure and Cannasoul Sign Strategic Investment and Collaboration Agreements to Advance Cannabis Science and Pharmaceutical Innovation

Core Insights - InterCure has entered into a definitive Share Purchase Agreement and a Collaboration Agreement with Cannasoul R&D Ltd, acquiring a 28% ownership stake in Cannasoul with an option to increase to 51% within two years [1][2] - The collaboration aims to combine InterCure's pharmaceutical platform with Cannasoul's research capabilities to develop evidence-based cannabis therapeutics [1][4] - The agreements come at a pivotal moment for the U.S. cannabis market, as the Trump administration is reportedly considering rescheduling cannabis, which could create significant opportunities for international cannabis companies like InterCure [2][4] Company Overview - InterCure Ltd. operates as Canndoc and is Israel's largest licensed cannabis producer, known for its pharmaceutical-grade medical cannabis products [5] - The company utilizes a vertically integrated "seed-to-sale" model and has a strong distribution network, positioning itself as a leader in the global cannabis market outside North America [5] Research and Development - Prof. Dedi Meiri, a prominent cannabis researcher, is expected to chair InterCure's newly established Scientific Advisory Board, enhancing the integration of Cannasoul's analytics into InterCure's operations [3][4] - The partnership aims to accelerate the development of next-generation cannabis therapeutics, leveraging Cannasoul's advanced research capabilities [3][4] Market Context - The potential rescheduling of cannabis from Schedule I to Schedule III by the Trump administration could transform the regulatory landscape, unlocking new opportunities for companies like InterCure [2][4]